Evidence map›Paper›PMID 31542053›Full record

ArticleJournal of medical case reports2019

Hepatitis B virus reactivation sustained by a hepatitis B virus surface antigen immune-escape mutant isolate in a patient who was hepatitis B core antibody positive during treatment with sofosbuvir and velpatasvir for hepatitis C virus infection: a case report.

Luca Foroghi Biland, Ludovica Ferrari, Vincenzo Malagnino, Elisabetta Teti, Carlotta Cerva, Adele Gentile, Marianna Aragri, Romina Salpini, Valentina Svicher, Massimo Andreoni and 1 more

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medical case reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Luca Foroghi BilandInfectious Diseases Clinic, Policlinico Tor Vergata, Rome, Italy.
Ludovica FerrariInfectious Diseases Clinic, Policlinico Tor Vergata, Rome, Italy.
Vincenzo MalagninoInfectious Diseases Clinic, Policlinico Tor Vergata, Rome, Italy.
Elisabetta TetiInfectious Diseases Clinic, Policlinico Tor Vergata, Rome, Italy.
Carlotta CervaInfectious Diseases Clinic, Policlinico Tor Vergata, Rome, Italy.
Adele GentileInfectious Diseases Clinic, Policlinico Tor Vergata, Rome, Italy.
Marianna AragriDepartment of Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy.
Romina SalpiniDepartment of Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy.
Valentina SvicherDepartment of Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy.
Massimo AndreoniInfectious Diseases Clinic, Policlinico Tor Vergata, Rome, Italy.
Loredana SarmatiInfectious Diseases Clinic, Policlinico Tor Vergata, Rome, Italy. sarmati@med.uniroma2.it.
Policlinico Tor Vergata · ITUniversity of Rome Tor Vergata · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlthough several cases of hepatitis B virus reactivation have been described in patients with a history of hepatitis B virus infection while undergoing treatment for hepatitis C virus infection with direct acting antivirals, the question of whether hepatitis B virus surface antigen immune-escape mutations might play a role has not been addressed so far. CASE PRESENTATION: We report a case of hepatitis B virus reactivation in a Caucasian patient infected with hepatitis C virus during treatment with sofosbuvir and velpatasvir. A 50-year-old man with a genotype 1a hepatitis C virus infection was considered for therapy. His serological profile was hepatitis B virus surface antigen-negative, hepatitis B virus core antibody-positive, hepatitis B virus surface antibody-negative, and anti-hepatitis D virus-positive. The detection of hepatitis B virus deoxyribonucleic acid (DNA) indicated active viral replication during the direct acting antiviral treatment that spontaneously returned to undetectable levels after treatment completion. Starting from week 12 after the end of treatment, hepatitis B virus surface antibody titers and hepatitis B virus e antibody developed. Sequencing analysis revealed the hepatitis B virus genotype D3 and the presence of two relevant immune-escape mutations (P120S and T126I) in the major hydrophilic region by analyzing the S region.

conclusionsWe speculate that the presence of the hepatitis B virus surface antigen mutations, endowed with the enhanced capability to elude the immune response, could play a role in hepatitis B virus reactivation. This observation confirms that occult hepatitis B infection should also be carefully monitored, through surveillance of the hepatitis B virus viral load before and during direct acting antiviral treatment of hepatitis C virus.

Indexed as

MutationAntiviral AgentsBenzimidazolesBenzopyransCarbamatesCoinfectionDrug Therapy, CombinationGenotypeHepatitis BHepatitis B AntibodiesHepatitis B Surface AntigensHepatitis B virusHepatitis C, ChronicHeterocyclic Compounds, 4 or More RingsHumansMaleAntiviral AgentsBenzimidazolesBenzopyransCarbamatesHepatitis B AntibodiesHepatitis B Surface AntigensHeterocyclic Compounds, 4 or More RingsSofosbuvirvelpatasvirCoinfection HBV/HCVDirect acting antiviralsHBV reactivationHepatitis B virusImmune-escape HBV mutant

Identifiers

PMID31542053
PMCPMC6754855
OpenAlexW2973544571

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.